EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer

Area of Science:

• Cell Biology
• Molecular Biology
• Cancer Research

Background:

• Nuclear pore transport, mediated by importins and exportins, regulates protein activity.
• Cancer cells exploit nuclear transport for tumorigenesis, but mechanisms are unclear.
• Epidermal growth factor receptor (EGFR) is crucial in development and cancer.

Purpose of the Study:

• To elucidate the role of RAN-binding protein 6 (RanBP6) in EGFR regulation and cancer.
• To investigate the mechanism by which RanBP6 influences signal transducer and activator of transcription 3 (STAT3) and EGFR expression.

Main Methods:

• Investigated RanBP6 function using gene silencing techniques.
• Analyzed the impact of RanBP6 on STAT3 nuclear translocation and EGFR promoter binding.
• Examined EGFR transcriptional regulation and pathway output.
• Correlated RanBP6 locus deletions with glioblastoma (GBM) patient data.
• Assessed the effect of RanBP6 silencing on glioma growth in vivo.

Main Results:

• RanBP6 silencing inhibited STAT3 nuclear translocation and its binding to the EGFR promoter.
• EGFR transcription was derepressed, leading to increased EGFR pathway signaling.
• Focal deletions of the RanBP6 locus were identified in a subset of GBM.
• RanBP6 silencing promoted glioma growth in experimental models.

Conclusions:

• RanBP6 acts as a regulator of EGFR by controlling STAT3 nuclear import.
• EGFR deregulation in cancer can occur through the silencing of nuclear import pathway components.
• RanBP6 is a potential tumor suppressor in glioblastoma, and its loss contributes to glioma progression.